drugset / Trial / NCT00097435

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

NCT00097435

Phase 2 Completed 115 enrolled Human Genome Sciences Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.

Timeline

Start
2004-10
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Albuferon Protein / enzyme biologic
Background Ribavirin Small molecule